期刊文献+

乳腺典型髓样癌与非典型髓样癌的超声诊断分析 被引量:6

Analysis of typical and atypical breast medullary carcinoma diagnosed by ultrasound
原文传递
导出
摘要 目的探讨高频彩色多普勒超声对乳腺髓样癌的诊断价值。方法 56例乳腺髓样癌患者,均为女性,年龄25~87岁,平均年龄50.92岁;其中典型髓样癌35例,非典型髓样癌21例。患者手术前行乳腺超声检查,先用灰阶超声观察肿块的部位、大小、形态、边界、内部回声、有无钙化、后方回声增强或衰减,再启用彩色多普勒血流显像(CDFI)检查肿块的血流信号,频谱多普勒分析肿块血流阻力指数(RI),最后检查腋窝淋巴结有无肿大。结果乳腺髓样癌发生于左侧乳腺者占57.14%,高于右侧乳腺的42.86%,但差异无统计学意义(P>0.05)。典型髓样癌最大径平均值为2.39cm,略小于非典型髓样癌的2.52cm(P>0.05)。与非典型髓样癌比较,典型髓样癌形态较规则、边界较清楚、内部回声较均匀,多伴后方回声增强,钙化较少见。乳腺髓样癌血液供应多较丰富,该组32例典型髓样癌、18例非典型髓样癌进行了CDFI检查,血流Ⅱ/Ⅲ级者分别占65.63%、61.11%(P>0.05),其中20例进行了多普勒频谱分析,RI>0.70。结论典型髓样癌与非典型髓样癌在肿块的边界、回声均匀与否,有无钙化及后方回声增强等超声表现明显不同,术前高频彩色多普勒超声检查具有重要诊断价值。 Objective To investigate the diagnostic value of high frequency ultrasound on breast medullary carcinoma.Methods A total of 56 female breast medullary carcinoma patients were enrolled,aged 25-87 years old,mean age 50.92 years old.Thirty-five were typical and 21 were atypical.All of them received preoperative ultrasound examination.The mass location,size,shape,boundary,internal echo,calcification and posterior echo were observed by gray-scale mode ultrasound.After that,the mass blood supply was detected using color Doppler flow imaging(CDFI),and the resistance index(RI) was measured by pulsed-wave Doppler.Results The incidence rate of medullary carcinoma in left breast was 57.14 %(32/56),which was higher than that in the right(42.86 %,24/56)(P 0.05).The mean maximum diameter of atypical medullary carcinoma(2.39 cm) was slightly smaller than that of the typical(2.52 cm)(P 0.05).Compared with the atypical medullary carcinoma,the typical showed more regular shape,clear boundary,homogeneous internal echo,enhanced posterior echo,but less calcification.According to Doppler ultrasound examination,65.63 % typical and 61.11 % atypical medullary carcinoma displayed abundant blood flow,and 100.0 %(20/20) medullary carcinoma showed RI 0.70.Conclusion The high frequency color Doppler ultrasound showed different appearances between typical and atypical medullary carcinoma in mass boundary,internal echo,calcification and posterior echo,which would be a significant method for the disease diagnosis.
出处 《生物医学工程与临床》 CAS 2012年第1期50-53,F0003,共5页 Biomedical Engineering and Clinical Medicine
关键词 髓样癌 乳腺 彩色多普勒超声 诊断 medullary carcinoma breast color Doppler ultrasound diagnosis
  • 相关文献

参考文献10

  • 1Perkins GH,Green MC,Middleton LP,et al.Medullary breast carcinoma:outcomes and prognosis with the utilization of chemotherapy[J].J Clin Oncol,2004,22(14S):671.
  • 2Kiyamova R,Kostianets O,Malyuchik S,et al.Identification oftumor-associated antigens from medullary breast carcinoma by a modified SEREX approach[J].Mol Biotechnol,2010,46 (2):105-112.
  • 3Park SH,Kim MJ,Park BW,et al.Impact of preoperative ultrasonography and fine-needle aspiration of axillary lymph nodes on surgical management of primary breast cancer[J].Ann Surg Oncol,2011,18(3):738-744.
  • 4Wang X,Xu P,Wang Y,et al.Contrast-enhanced ultrasonographic findings of different histopathologic types of breast cancer[J].Acta Radiol,2011,52(3):248-255.
  • 5Nielsen DL,Andersson M,Andersen JL,et al.Antiangiogenic therapy for breast cancer[J].Breast Cancer Res,2010,12(5):209.
  • 6Oh SJ,Kim O,Lee JS,et al.Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells[J].Food Chem Toxicol,2010,48(11):3227-3234.
  • 7吴丽足,林礼务,何以敉,高上达,林学英,王艳.高频彩色多普勒超声在乳腺髓样癌与腺纤维瘤鉴别诊断中的价值[J].中国超声医学杂志,2009(8):738-741. 被引量:21
  • 8张晋熙,姜玉新.浅表器官及组织超声诊断学[M].北京:科学技术文献出版社,2006:1-2,174-176,192-196.
  • 9王玉霞,徐香玖.乳腺癌的钼靶X线表现、病理与分子生物学指标的相关性研究[J].中国医学影像技术,2008,24(1):60-63. 被引量:20
  • 10李晓曦,王深明,赖远辉,李松奇.乳腺髓样癌的治疗[J].中华外科杂志,2005,43(23):1516-1518. 被引量:4

二级参考文献27

共引文献43

同被引文献37

  • 1Ridolfi RL,Rosen PP,Port A,et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow up [J]. Cancer,1977,40(4) :1365-1385.
  • 2Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER 2 positive advanced breast cancer[J]. N Engl J Med, 2006,355 (26): 2733-2743.
  • 3Lin A,Rugo HS. The role of trastuzumab in early stage breast eancer:current data and treatment reeommendations [J]. Curr Treat Options Oncol, 2007,8 (1): 47-60.
  • 4Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for meta- static disease[J]. J Clin Oncol, 1999,17(9): 2639-2648.
  • 5Slamon DJ, Godolphin W, Jones LA, et al. Studies of HER 2/ neu protooncogene in human breast and ovarian cancer[J]. Sci ence, 1989,244(4905): 707-712.
  • 6Arihiro K,Oda M, Ogawa K, et al. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples [J]. Jpn J Clin Oncol, 2013,43(1): 55-62.
  • 7Xu R, Feiner H, Li P, et al. Differential amplification and overex- pression of HER 2/neu, p53, MIB1, and estrogenreceptor/pro- gesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast[J]. Arch Pathol Lab Med,2003,127(11) :1458-1464.
  • 8Marginean F,Rakha EA, Ho BC, et al. Histological features of me- dullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast[J]. Mod Pathol, 2010,23(10) :1357-1363.
  • 9Cao AY, He M, H uang L, et al. Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China:a comparison with infiltrating ductalcarcino ma not otherwise specified[J]. World J Surg Oncol, 2013, 11 (1):91.
  • 10Hanagiri T, Ono K, Baba T, et al.Clinicopathologic characteristics of mucinous carcinoma of the breast.lnt Surg, 2010, 95( 3 ) : 126-129.

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部